<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412018000300002</article-id>
<article-id pub-id-type="doi">10.24245/gom.v86i3.1690</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Ácido tranexámico: una alternativa terapéutica en pacientes con síndrome de HELLP]]></article-title>
<article-title xml:lang="en"><![CDATA[Tranexamic acid: A therapeutic alternative in patients with HELLP syndrome]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García de la Torre]]></surname>
<given-names><![CDATA[José Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Cantú]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Robles]]></surname>
<given-names><![CDATA[Arnoldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soto-Zataraín]]></surname>
<given-names><![CDATA[Jorge L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario de Saltillo, Coahuila  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario de Saltillo  ]]></institution>
<addr-line><![CDATA[ Coahuila]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario de Saltillo  ]]></institution>
<addr-line><![CDATA[ Coahuila]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Universitario de Saltillo  ]]></institution>
<addr-line><![CDATA[ Coahuila]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2018</year>
</pub-date>
<volume>86</volume>
<numero>3</numero>
<fpage>165</fpage>
<lpage>173</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412018000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412018000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412018000300002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO  Evaluar si la prescripción de ácido tranexámico a pacientes con síndrome de HELLP mejora su curso clínico en forma general.  MATERIALES Y MÉTODOS  Estudio retrospectivo, analítico y comparativo al que se incluyeron dos grupos de pacientes con diagnóstico de síndrome de HELLP atendidas entre enero de 2015 y diciembre de 2016 en el servicio de Ginecología y Obstetricia del Hospital Universitario de Saltillo. A un grupo se le indicó ácido tranexámico y al control ningún medicamento.  RESULTADOS  Se incluyeron 18 pacientes, 9 en cada grupo. Parámetros de laboratorio: plaquetas mayores a 105 vs menores a 105 en el grupo control. La deshidrogenasa láctica (DHL) tuvo un decremento de 58 vs 16% en las pacientes tratadas en las primeras 48 horas. La aspartato aminotransferasa (TGO) mejoró 56 vs 43% en el grupo control y la alanina aminotransferasa (TGP) mejoró 31 vs 20% en el grupo control, ambas en las primeras 24 horas. La cuantificación de proteínas en orina en 24 horas reportó 2867 mg versus 3378 mg en el grupo control. La hemoglobina permaneció siempre en cifras superiores a 11 vs 9.92 g/dL del grupo control. Los días de estancia en la unidad de cuidados intensivos fue de 3 vs 4.16 del grupo control.  CONCLUSIONES  Hacen falta más estudios con asignación al azar, con una muestra más amplia, para valorar las ventajas y efectos del ácido tranexámico en pacientes con síndrome de HELLP. La prescripción de este medicamento representa una alternativa en el tratamiento del síndrome de HELLP, que proporciona un beneficio clínico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE To stablish if the use of tranexamic acid (TXA) in patients with HELLP syndrome improves the clinic curse in general terms.  MATERIALS AND METHODS  Analytic, comparative and retrospective study where two groups of patients are included, which assisted to the obstetrics and gynecology service in the Hospital Universitario de Saltillo, where the diagnosis of HELLP syndrome was made. Tranexamic acid was given to one of the groups versus the control group without the drug.  RESULTS  18 patients were included, 9 in each group. The following was observed respect to the laboratory parameters: platelets greater than 105 vs smaller than 105 in the control group. The lactate dehydrogenase (DHL) had a decrease of 58 vs 16% in the patients without tranexamic acid in the first 48 hours. The aspartate aminotransferase (AST) improved 56 vs 43% in the control group, and the alanine aminotransferase (ALT) improved 31 vs 20% in the control group, both in the first 24 hours. The report of protein quantification in 24 hours was 2867 vs 3378 mg in the control group. The hemoglobin figures remained greater than 11vs 9.92 g/dL of the control group. The days of stay in the intensive care unit (UCI) were 3 vs 4.16 of the control group.  CONCLUSIONS:  Randomized studies are required with an extended sample, to value the benefits and effects of the tranexamic acid, in this kind of patients. According to the collected data the use of tranexamic acid represents an alternative in the treatment of HELLP syndrome, which provides a clinic benefit.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Ácido tranexámico]]></kwd>
<kwd lng="es"><![CDATA[síndrome de HELLP]]></kwd>
<kwd lng="es"><![CDATA[preeclampsia]]></kwd>
<kwd lng="es"><![CDATA[deshidrogenasa láctica]]></kwd>
<kwd lng="en"><![CDATA[Tranexamic acid]]></kwd>
<kwd lng="en"><![CDATA[HELLP syndrome]]></kwd>
<kwd lng="en"><![CDATA[Pre-eclampsia]]></kwd>
<kwd lng="en"><![CDATA[Lactate dehydrogenase]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haram]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Svendsen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Abildgaard]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The HELLP syndrome clinical issues and management. A Review]]></article-title>
<source><![CDATA[BMC Pregnancy Childbirth]]></source>
<year>2009</year>
<volume>9</volume>
<page-range>8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Habli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Eftekhari]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wiebracht]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term maternal and subsequent pregnancy outcomes 5 years after hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2009</year>
<volume>201</volume>
<numero>385</numero>
<issue>385</issue>
<page-range>e1-.e5</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sibai]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count]]></article-title>
<source><![CDATA[Obstetrics and Gynecology]]></source>
<year>2004</year>
<volume>103</volume>
<page-range>981-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitzpatrick]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Hinshaw]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kurinczuk]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Knight]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors, management, and outcomes of hemolysis, elevated liver enzymes, and low platelets syndrome and elevated liver enzymes, low platelets syndrome]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2014</year>
<volume>123</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>618-27</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hay]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liver disease in pregnancy]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2008</year>
<volume>47</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1067-76</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hubel]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is oxidative stress the link in the two-stage model of pre-eclampsia]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>354</volume>
<numero>9181</numero>
<issue>9181</issue>
<page-range>788-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Lain]]></surname>
<given-names><![CDATA[KY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent insights into the pathogenesis of pre-eclampsia]]></article-title>
<source><![CDATA[Placenta]]></source>
<year>2002</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>359-72</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hubel]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The two stage model of preeclampsia: variations on the theme]]></article-title>
<source><![CDATA[Placenta]]></source>
<year>2009</year>
<numero>30^sSUPPL</numero>
<issue>30^sSUPPL</issue>
<supplement>SUPPL</supplement>
<page-range>32-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Quaglia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Westbrook]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Heneghan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liver disease in pregnancy]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>375</volume>
<page-range>594-605</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boregowda]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Shehata]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gastrointestinal and liver disease in pregnancy]]></article-title>
<source><![CDATA[Best Pract Res Clin Obstet Gynaecol]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>835-53</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sziller]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hupuczi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Normand]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Halmos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Papp]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Witkin]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fas (TNFRSF6) gene polymorphism in pregnant women with hemolysis, elevated liver enzymes, and low platelets and in their neonates]]></article-title>
<source><![CDATA[Obstet Gynecol]]></source>
<year>2006</year>
<volume>107</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>582-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Savli]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Molvarec]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vascular endothelial growth factor (VEGF) polymorphisms in HELLP syndrome patients determined by quantitative real time PCR and melting curve analyses]]></article-title>
<source><![CDATA[Clinica Chimica Acta]]></source>
<year>2008</year>
<volume>389</volume>
<page-range>126-31</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muetze]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leeners]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ortlepp]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maternal factor V Leiden mutation is associated with HELLP syndrome in Caucasian women]]></article-title>
<source><![CDATA[Acta Obstetricia et Gynecologica Scandinavica]]></source>
<year>2008</year>
<volume>87</volume>
<page-range>635-42</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yucesoy]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ozkan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bodur]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy a seven-year experience of a tertiary care center]]></article-title>
<source><![CDATA[Arch Gynecol Obstet]]></source>
<year>2005</year>
<volume>273</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yucesoy]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cakiroglu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bodur]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ozkan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An analysis of HELLP syndrome cases Does platelet count predict adverse maternal and fetal outcomes in women with HELLP syndrome?]]></article-title>
<source><![CDATA[Arch Gynecol Obstet]]></source>
<year>2011</year>
<volume>283</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>941-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khumsat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and risk factors of HELLP syndrome in thai pregnant women with severe pre-eclampsia]]></article-title>
<source><![CDATA[Thai J Obstet Gynaecol]]></source>
<year>2008</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>192-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauserman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lokangaka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thorsten]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for maternal death and trends in maternal mortality in low- and middle-income countries: A prospective longitudinal cohort analysis]]></article-title>
<source><![CDATA[Reprod Health]]></source>
<year>2015</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheppard]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Bonnar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrinolysis in decidual spiral arteries in late pregnancy]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>1978</year>
<volume>39</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>751-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[McLintock]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lockhart]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postpartum hemorrhage: When uterotonics and sutures fail]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2012</year>
<volume>87</volume>
<numero>^sSuppl. 1</numero>
<issue>^sSuppl. 1</issue>
<supplement>Suppl. 1</supplement>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Zirqi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Vangen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Forsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and risk factors of severe obstetric haemorrhage]]></article-title>
<source><![CDATA[BJOG]]></source>
<year>2008</year>
<volume>115</volume>
<page-range>1265-72</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novikova]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hofmeyr]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tranexamic acid for preventing postpartum haemorrhage]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2010</year>
<page-range>CD007872</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sócrates Aedo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paulina Lira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Constanza Rivas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Patricio Narváez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Italo Campodónico]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ácido tranexámico en obstetricia y ginecología Rev. Obstet. Ginecol. Hosp. Santiago Oriente Dr]]></article-title>
<source><![CDATA[Luis Tisné Brousse]]></source>
<year>2013</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>143-56</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peitsidis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kadir]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum]]></article-title>
<source><![CDATA[Expert Opin Pharmacother]]></source>
<year>2011</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>503-16</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sydenh]]></surname>
<given-names><![CDATA[AME]]></given-names>
</name>
<name>
<surname><![CDATA[Blackhall]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shakur]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-fibrinolytic agents in post partum haemorrhage a systematic review]]></article-title>
<source><![CDATA[BMC Pregnancy and Childbirth]]></source>
<year>2009</year>
<volume>9</volume>
<page-range>29</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osmanagaoglu]]></surname>
<given-names><![CDATA[Mehmet Armagan]]></given-names>
</name>
<name>
<surname><![CDATA[Osmanagaoglu]]></surname>
<given-names><![CDATA[Selen]]></given-names>
</name>
<name>
<surname><![CDATA[Ulusoy]]></surname>
<given-names><![CDATA[Hülya]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkaya]]></surname>
<given-names><![CDATA[Hasan]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maternal outcome in HELLP syndrome requiring intensive care management in a Turkish hospital]]></article-title>
<source><![CDATA[Sao Paulo Med]]></source>
<year>2006</year>
<volume>124</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>85-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<source><![CDATA[Acuerdo AS3.HCT.270116/8.P.DF dictado por el H. Consejo Técnico en la sesión ordinaria celebrada el día 27 de enero de dos mil dieciséis, relativo a la aprobación de los costos unitarios por Nivel de Atención Médica para el ejercicio fiscal 2016]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
